Legal entity

Duchenne muscular dystrophy

Technology

Every one of those 1 sits in a single category, regulation. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.

Last mentioned: Mar 10, 2026

Entity pulse

Recent coverage · Duchenne muscular dystrophy

1 story
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Duchenne muscular dystrophy

Every one of those 1 sits in a single category, regulation. FDA is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. The 6 average consequence score is below the beat benchmark of 6.3 in the same window. Duchenne muscular dystrophy appears in 1 tracked Legal story from March 10, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 38 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Duchenne muscular dystrophy. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Document Request

    Expected date for formal requests for internal FDA communications regarding DMD drug applications.

  2. Investigation Announced

    Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.

  3. Commissioner Consultation

    Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.

Stories mentioning Duchenne muscular dystrophy 1

Regulation Neutral

Senator Johnson Launches Investigation into FDA Rare Disease Drug Denials

Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.

2 sources

Source: MedPage Today · STAT News

Duchenne muscular dystrophy is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.